Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "Pharmaceuticals"

1387 News Found

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Drug Approval | November 11, 2024

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension


Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant
Startup | November 11, 2024

Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant

The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring


Granules India’s Unit V facility secures USFDA EIR with NAI status
Drug Approval | November 10, 2024

Granules India’s Unit V facility secures USFDA EIR with NAI status

The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
News | November 06, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.


Emcure Pharma forms subsidiary to strengthen dermatology portfolio
News | November 04, 2024

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


Mankind Pharma completes acquisition of BSV
News | October 25, 2024

Mankind Pharma completes acquisition of BSV

Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.